Our Services
Medical Information
Helpful Resources
Published on: 9/22/2026
Farxiga's active ingredient is dapagliflozin, and generic versions have received FDA approval, though U.S. availability has been limited by patent protections and exclusivity timelines that only recently began to expire. An FDA-approved generic must contain the same active ingredient at the same strength and be bioequivalent, meaning it works the same way in the body, but inactive ingredients, appearance, and pricing can differ. Coverage, pharmacy stock, and whether a generic or an authorized generic is offered vary widely, so what you pay may not change as much as expected. There are several important details to consider before switching, including dosing, formulation, and why dapagliflozin was prescribed for you, all explained below.
If you are weighing a switch or noticing new symptoms while managing diabetes, heart failure, or kidney disease, it helps to sort out what needs attention now versus what can wait for your next appointment. A free, instant, online symptom check can help you organize your symptoms, understand possible causes, and plan clear next steps before you talk with a pharmacist or clinician.
Last reviewed for medical accuracy: 09/22/2026
Is There a Farxiga Generic Available, and Is It the Same Drug?
Farxiga (generic name: dapagliflozin) is a prescription medication used to help manage type 2 diabetes and, more recently, certain heart and kidney conditions. Like many brand‐name drugs, Farxiga faced the eventual introduction of a generic version. Below, we’ll explain what a Farxiga generic is, how it compares to the brand‐name medicine, and what you should know before considering a switch.
Farxiga belongs to a class of drugs called SGLT2 inhibitors. It works by helping your kidneys remove excess glucose (sugar) from the body through urine. Originally approved by the U.S. Food and Drug Administration (FDA) in 2014 for type 2 diabetes, Farxiga’s indications have since expanded to include:
Key points about Farxiga:
Yes, there is a generic version of Farxiga. In March 2020, the FDA approved the first generic dapagliflozin tablets. Since then, multiple manufacturers have launched their own dapagliflozin products.
Yes. By law and by design, a Farxiga generic (dapagliflozin) is bioequivalent to the brand‐name Farxiga. This means:
What may differ between brand and generic:
These differences do not affect how the drug works.
Cost savings
Wider insurance coverage
Proven quality
While generics are safe and effective, you may notice small differences or have questions:
Always check with your pharmacist or doctor before switching, especially if you have a history of sensitivity to medication components.
Whether you take brand‐name Farxiga or a generic, the side‐effect profile is the same. The most common side effects include:
Less common but serious risks (contact a doctor immediately if they occur):
Consider trying a free, online symptom check, using the doctor approved Ubie Symptom Checker before your next appointment to track how you’re feeling and prepare questions for your doctor.
If you’re interested in switching to a generic dapagliflozin, here are steps to take:
If you ever experience serious symptoms—severe abdominal pain, trouble breathing, or symptoms of ketoacidosis—seek medical attention right away. For any ongoing concerns or to manage symptoms, speak to a doctor about what’s best for your health.
(References)
* LaCreta F, Griffen SC, Liu X, Smith C, Hines C, Volk K, Tejwani R, Boulton DW. Bioequivalence and food effect of heat-stressed and non-heat-stressed dapagliflozin 2.5- and 10-mg tablets. Int J Pharm. 2016 Sep 10;511(1):288-295. doi: 10.1016/j.ijpharm.2016.07.017. Epub 2016 Jul 12. PMID: 27418571.
* Cho HJ, Woo MR, Cho JH, Kim Y Il, Choi HG. Novel dapagliflozin di-L-proline cocrystal-loaded tablet: preparation, physicochemical characterization, and pharmacokinetics in beagle dogs and mini-pigs. Pharm Dev Technol. 2022 Mar;27(3):331-340. doi: 10.1080/10837450.2022.2052320. Epub 2022 Mar 25. PMID: 35264063.
* Fatima Z, Atal S, Joshi R, Sadasivam B. Implications and Economic Impact of Applying International Guidelines and Recommendations to the Management of High-Risk Group of Type 2 Diabetes Mellitus Patients in India. Cureus. 2022 Feb;14(2):e22141. doi: 10.7759/cureus.22141. Epub 2022 Feb 11. PMID: 35308676; PMCID: PMC8920807.
* Banerjee M, Pal R, Nair K, Mukhopadhyay S. SGLT2 inhibitors and cardiovascular outcomes in heart failure with mildly reduced and preserved ejection fraction: A systematic review and meta-analysis. Indian Heart J. 2023 Mar-Apr;75(2):122-127. doi: 10.1016/j.ihj.2023.03.003. Epub 2023 Mar 11. PMID: 36914068; PMCID: PMC10123444.
* Kang SJ, Kim JE. Development of Clinically Optimized Sitagliptin and Dapagliflozin Complex Tablets: Pre-Formulation, Formulation, and Human Bioequivalence Studies. Pharmaceutics. 2023 Apr 14;15(4). doi: 10.3390/pharmaceutics15041246. Epub 2023 Apr 14. PMID: 37111730; PMCID: PMC10141516.
* Yang M, Kondo T, Talebi A, Jhund PS, Docherty KF, Claggett BL, Vaduganathan M, Bachus E, Hernandez AF, Lam CSP, Inzucchi SE, Martinez FA, de Boer RA, Kosiborod MN, Desai AS, Køber L, Ponikowski P, Sabatine MS, Solomon SD, McMurray JJV. Dapagliflozin and quality of life measured using the EuroQol 5-dimension questionnaire in patients with heart failure with reduced and mildly reduced/preserved ejection fraction. Eur J Heart Fail. 2024 Jul;26(7):1524-1538. doi: 10.1002/ejhf.3263. Epub 2024 May 3. PMID: 38700986.
* Yang M, Kondo T, Talebi A, Jhund PS, Docherty KF, Claggett BL, Vaduganathan M, Bachus E, Hernandez AF, Lam CSP, Martinez FA, de Boer RA, Kosiborod MN, Desai AS, Køber L, Ponikowski P, Sabatine MS, Solomon SD, McMurray JJV. EuroQol 5-Dimension Questionnaire in Heart Failure With Reduced, Mildly Reduced, and Preserved Ejection Fraction: A Patient-Level Analysis of DAPA-HF and DELIVER. JACC Heart Fail. 2025 Feb;13(2):277-292. doi: 10.1016/j.jchf.2024.10.020. PMID: 39909641.
* Du P, Chen X, Xu Y, Zhou Y, Gao H. Drug-Associated Ketoacidosis: A Comprehensive Disproportionality Analysis Based on the FAERS Database. Diabetes Obes Metab. 2026 Jul;28(7):5893-5906. doi: 10.1111/dom.70790. Epub 2026 Apr 20. PMID: 42010884.
* Anderer S. FDA Approves Generic Dapagliflozin. JAMA. 2026 May 19;335(19):1655. doi: 10.1001/jama.2026.2120. PMID: 42030058.
* Prasath JH, Garg U, Kurapati K, Baro Agarwal A, Singhal P, Anthuvan T, Gadia S, Gupta A, B SS. Bioequivalence of Fixed-Dose Dapagliflozin-Pioglitazone in Healthy Indian Adults: Results From the Randomized Crossover PRO-4 Study. Cureus. 2026 Jul;18(7):e111872. doi: 10.7759/cureus.111872. Epub 2026 Jul 1. PMID: 42540286; PMCID: PMC13425340.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.